---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-295622"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2026-07-06T12:15:35+00:00"
generated_at: "2026-07-06T12:20:06.738018+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Corbus appoints Leonardo Viana Nicacio as CMO; base salary $545K, equity $2.1M

## Summary
- Dr. Nicacio appointed CMO effective Aug 3, 2026; base salary $545K, target bonus up to 40%, equity inducement awards of $2.1M.
- He brings ADC and HPV-driven oncology experience, previously CMO at Protara, VP at Seagen (TIVDAK), and roles at AstraZeneca, Flatiron Health.
- Corbus expects to initiate TEMPO-1 registrational study of CRB-701 in 2L OPSCC summer 2026; topline CANYON-1 obesity study data late summer 2026.
- Employment agreement for 2 years, includes non-compete (6 months post) and non-solicitation (12 months post), severance provisions.

## SEC filing metadata
- accession: 0001193125-26-295622
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2026-07-06T12:15:35+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000119312526295622/0001193125-26-295622-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000119312526295622/crbp-20260702.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-295622
- JSON: https://secwatch.observer/filing/0001193125-26-295622.json
- Plain text: https://secwatch.observer/filing/0001193125-26-295622.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.